Serum Factor V Is a Continuous Biomarker of Graft Dysfunction and a Predictor of Graft Loss After Liver Transplantation
| Autor: | Aljamir Duarte Chedid, Alexandre de Araujo, Mário Reis Álvares-da-Silva, Tomaz J. M. Grezzana-Filho, Carolina Prediger, Gonzalo Sapisochin, Marcio F. Chedid, Andre Gorgen, João E Prediger, Ian Leipnitz, Ariane Nádia Backes, Cleber Rosito Pinto Kruel |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Graft Rejection Male medicine.medical_specialty Graft dysfunction medicine.medical_treatment 030230 surgery Liver transplantation Graft loss Logistic regression Gastroenterology 03 medical and health sciences Young Adult 0302 clinical medicine Primary outcome Internal medicine medicine Humans Retrospective Studies Transplantation biology business.industry Factor V Retrospective cohort study Middle Aged Prognosis Liver Transplantation biology.protein Biomarker (medicine) Feasibility Studies 030211 gastroenterology & hepatology Female Primary Graft Dysfunction business Biomarkers |
| Zdroj: | Transplantation. 103(5) |
| ISSN: | 1534-6080 |
| Popis: | Factor V has never been compared to a validated early allograft dysfunction (EAD) definition. We aimed to assess factor V as a biomarker of EAD and a predictor of graft loss after liver transplantation (LT).We retrospectively assessed the serum factor V levels on postoperative day 1 after LT. Patients were divided according to their factor V levels into the ≤36.1 U/mL and36.1 U/mL groups. The primary outcome was graft loss within 1, 3, and 6 months. The secondary outcome was EAD, as defined by Olthoff et al. Predictors of outcomes were identified by multivariable logistic regression.Two hundred twenty-seven patients were included in the study: 74 with factor V of 36.1 U/mL or less and 153 with factor V36.1 U/mL. EAD was diagnosed in 41 (55.4%) of 74 patients with factor V of 36.1 U/mL or less and in 20/153 (13.1%) patients with factor V36.1 U/mL (P0.001). According to the multivariable regression model, factor V was a continuous marker of EAD (odds ratio [OR], 0.96; 95% confidence interval [CI], 0.94-0.98 per U/mL). Among the study groups, the 1-, 3-, and 6-month graft survival rates were 82%, 74%, and 74%, respectively, for patients with factor V of 36.1 U/mL or less and 98%, 95%, and 95%, respectively, for patients with factor V36.1 U/mL (P = 0.001). Factor V was a continuous predictor for 3- and 6-month graft losses (OR, 0.96; 95% CI, 0.94-0.99 and OR, 0.97; 95% CI, 0.94-0.99 per U/mL), whereas EAD was not significant when adjusted for factor V.Factor V is an early marker for EAD and is a continuous predictor of short-term graft loss after LT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|